Home › Diffuse Large B-Cell Lymphoma › Tennessee › Knoxville
Diffuse Large B-Cell Lymphoma clinical trials in Knoxville, TN
3 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Knoxville (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RecruitingPhase 2/3
- Tennessee Cancer Specialists ( Site 7000), Knoxville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Tennessee Cancer Specialists ( Site 7004), Knoxville
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- The University of Tennessee Medical Center ( Site 0142), Knoxville
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
Other studies in Knoxville
- Non-Small Cell Lung Cancer14 studies
- Obesity11 studies
- Lung Cancer10 studies
- Breast Cancer9 studies
- Cancer (all types)8 studies
- Metastatic Cancer7 studies
- Overweight7 studies
- Heart Failure7 studies
- Cardiovascular Disease6 studies
- COPD5 studies
- Type 2 Diabetes5 studies
- High Blood Pressure5 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.